Editing Castrate-Resistant Prostate Cancer (section)

====== Lutetium-177–PSMA-617 ======
* MOA: radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment
* '''VISION trial'''
** Population: 831 patients with metastatic castration-resistant prostate cancer previously treated with at least one androgen-receptor–pathway inhibitor and one or two taxane regimens and who had PSMA-positive gallium-68 (68Ga)–labeled PSMA-11 positron-emission tomographic–computed tomographic scans
** Randomized to 177Lu-PSMA-617 vs. standard of care
** Alternate primary end points: imaging-based progression-free survival and overall survival
** Results
*** Median follow-up 20.9 months
*** 177Lu-PSMA-617 significantly improved progression-free survival and overall survival
** Sartor, Oliver, et al."Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer." ''New England Journal of Medicine'' (2021).
* '''TheraP trial'''
** Phase 2 trial of 200 males with metastatic castration-resistant prostate cancer for whom cabazitaxel was considered the next appropriate standard treatment
** Randomized to 177Lu-PSMA-617 vs cabazitaxel
** Primary outcome: PSA response defined by a reduction of at least 50% from baseline.
** Results
*** Significantly improved PSA response with 177Lu-PSMA-617
** Hofman, Michael S., et al."[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial." ''The Lancet'' 397.10276 (2021): 797-804.